Peptide-based obesity pharmacotherapy has transformed metabolic medicine. This hub spans the full landscape — GLP-1 monotherapy, dual and triple agonists, amylin co-agonists (cagrilintide), oral options, and the practical side of dosing, plateaus and side-effect management.
Roughly 15% of SURMOUNT-1 participants lost less than 5% body weight after 72 weeks of tirzepatide — non-response is real. These are the eight most common research-backed reasons the scale will not budge, and what to audit before increasing the dose.
A head-to-head research comparison of Ozempic (semaglutide) and retatrutide as of early 2026. Covers mechanism, trial-published weight loss, approval status, cost, and the open questions a direct trial has not yet answered.
A plain-English look at how retatrutide was dosed in the Phase 2 obesity trial and how TRIUMPH-1 titrates to 6 mg or 12 mg maintenance. Includes a week-by-week titration table and a dose-response table from the published NEJM data.
A research-focused review of retatrutide side effects pulled from the NEJM Phase 2 obesity trial and early TRIUMPH Phase 3 readouts. Covers GI tolerability, cardiovascular signals, discontinuation rates, and how the triple agonist stacks up against semaglutide and tirzepatide.
For most of the GLP-1 era, Medicare has not covered weight-loss drugs for obesity alone. That has changed in pieces — through cardiovascular indications, through policy proposals, and through Medicare drug-price negotiation. Here is what Medicare beneficiaries can and cannot access in 2026.
Most dual agonists in late-stage obesity trials pair GLP-1 with GIP. Survodutide takes a different route — GLP-1 plus glucagon receptor activation. The dual mechanism produced ~19% weight loss and strong liver-fibrosis improvements in Phase 2. Here is why glucagon agonism matters.
Viking Therapeutics is a mid-cap biotech trying to carve a slice out of a market dominated by Lilly and Novo. Their lead asset VK2735 is a GLP-1/GIP dual agonist in two formulations — weekly injectable and daily oral tablet — with Phase 2 data that caught the market's attention.
Weekly injections may not be the final form of GLP-1 therapy. Amgen's MariTide is a monoclonal-antibody conjugate dosed once a month — not once a week — and the Phase 2 data suggest the magnitude of weight loss holds up. Here is how the molecule works and why monthly dosing matters.
For years, cross-trial comparisons told us tirzepatide outperformed semaglutide for weight loss. SURMOUNT-5 is the first randomised head-to-head trial that proved it directly. 20.2% versus 13.7% at 72 weeks — and the implications reach much further than one trial.
Novo Nordisk's CagriSema combines two peptides — cagrilintide (amylin analogue) and semaglutide (GLP-1) — in a single weekly injection. REDEFINE-1 produced 22.7% body weight loss at 68 weeks, falling short of the 25% target but putting Novo back in the race against Eli Lilly's tirzepatide and retatrutide. Here's the full data.
Orforglipron is the first oral, non-peptide GLP-1 receptor agonist to clear Phase 3. It needs no food or water timing, delivers 12.4% weight loss, and has a PDUFA goal date of April 10, 2026. Here's what the ATTAIN program showed and why pill-form GLP-1 therapy matters.
Eli Lilly's Phase 3 TRIUMPH-1 trial of retatrutide delivered up to 30.3% mean body weight loss at 104 weeks — the highest ever recorded in a pharmacological obesity trial. Here is what the data show, how it compares to tirzepatide and semaglutide, and what it means for the peptide landscape in 2026.
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes. This overview covers the clinical research behind its metabolic and weight-related effects.
AOD-9604 is a modified fragment of the C-terminus of human growth hormone, developed to isolate the lipolytic properties of HGH without the anabolic or diabetogenic effects.
As of 2026 Phase 3 data: retatrutide 12 mg (~30% body-weight loss, TRIUMPH-1) > tirzepatide 15 mg (~20%, SURMOUNT-5) > semaglutide 2.4 mg (~15%, STEP-1). Retatrutide is still investigational; tirzepatide and semaglutide are FDA-approved for chronic weight management.
Plateaus typically reflect new metabolic equilibrium: adaptive thermogenesis, reduced NEAT, and down-regulated satiety signaling at a lower body weight. Strategies include dose optimization, structured resistance training, and in some cases stepping up to a more potent agent.